Lepu Biopharma (HKG:2157) said it will resubmit its new drug application for nasopharyngeal cancer drug MRG003 with necessary supplementary materials to China's National Medical Products Administration on March 4, according to a Tuesday filing with the Hong Kong bourse.
MRG003 is an antibody-drug conjugate that targets EGFR on tumor cells, delivering a potent chemotherapy drug released inside the cell to trigger cancer cell death.
Previously, the NDA application was accepted by the administrator in September 2024 and was later withdrawn by the pharmaceutical company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。